AC-262536 is a non-steroidal selective androgen receptor modulator (SARM) found by Acadia Pharmaceuticals. It acts as a partial activator of the androgen receptor, has been studied only in animals, and is not FDA approved.
Also known as: AC-262,536, AC262536.
For AC-262536, there is no approved product and no published human trial, so there are no label strengths or studied human amounts.
AC-262536 is not FDA approved, and we could not find any published trial that gave it to people. FDA says SARMs are unapproved drugs that cannot be legally marketed in the US as dietary supplements or drugs, and lists risks including liver injury and acute liver failure, a higher risk of heart attack or stroke, and effects on fertility. WADA bans SARMs as a class under "other anabolic agents" (S1.2), in and out of competition; its 2026 list names several SARMs as examples, and the class is not limited to the ones it names.
In a 2-week study in castrated male rats (Piu 2008), it grew an androgen-sensitive muscle and lowered raised LH levels, with weak effects on the prostate and seminal vesicles compared with testosterone. Rat results often do not carry over to people. Anti-doping labs have since worked out how to detect it, including in horses given it by mouth (Cutler 2021).
We could not find a published human half-life or time to peak, so we do not list one. Figures quoted online usually come from animal studies or computer models.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator